Elsevier

Neuroscience Letters

Volume 229, Issue 3, 4 July 1997, Pages 161-164
Neuroscience Letters

In vivo inhibition of veratridine-evoked release of striatal excitatory amino acids by the group II metabotropic glutamate receptor agonist LY354740 in rats

https://doi.org/10.1016/S0304-3940(97)00442-4Get rights and content

Abstract

In vivo microdialysis in freely moving rats was used to investigate the presynaptic mechanisms by which LY354740, a novel, potent, selective, and systemically active agonist for group II metabotropic glutamate receptors (mGluRs), alters glutamate neuronal transmission. Basal levels of glutamate and aspartate in striatal dialysates of LY354740 (10 mg/kg i.p.)-treated animals were not significantly different from the saline-treated control animals. In the saline treated controls, veratridine (100 μM) induced a 6-fold increase in glutamate and 9-fold increase in aspartate. However, following LY354740 administration the veratridine-evoked release of glutamate and aspartate was completely prevented. These data demonstrate that LY354740 blocks the evoked release of endogenous excitatory amino acids, and indicate a role for group II mGluRs in presynaptic modulation of glutamate neuronal transmission in vivo.

Cited by (142)

  • Rescue of BDNF expression by the thalamic parafascicular nucleus with chronic treatment with the mGluR2/3 agonist LY379268 may contribute to the LY379268 rescue of enkephalinergic striatal projection neurons in R6/2 Huntington's disease mice

    2021, Neuroscience Letters
    Citation Excerpt :

    Excitotoxicity mediated by corticostriatal release of glutamate, made harmful by either excessive release or excessive postsynaptic activation of extrasynaptic NMDA receptors, has also been proposed to be involved in HD pathogenesis [27,28], and may also be among the additional processes that make R6/2 pathogenesis more rapid than seemingly could be achieved by cortical knockout of BDNF expression alone [1,2,6]. Corticostriatal and thalamostriatal terminals are enriched in mGluR2/3, which are negatively coupled to adenylyl cyclase [29] and thereby act as autoreceptors that dampen glutamate release [30-32]. An mGluR2/3 agonist such as LY379268 reduces glutamate release and thereby reduces activation of extrasynaptic NMDA-type glutamate receptors, which are thought to underlie excitotoxic injury to striatal neurons in HD [27,33].

  • A role for nucleus accumbens glutamate in the expression but not the induction of behavioural sensitization to ethanol

    2018, Behavioural Brain Research
    Citation Excerpt :

    The mGlu2/3 agonist, LY354740 (Tocris Bioscience), was dissolved in saline with dimethylsulfoxide to a 0.01% final concentration and was administered at 10 mg/kg, i.p., at an injection volume of 15 mL/kg, 20 min prior to EtOH administration. This dosing and time regimen has previously been shown to block striatal synaptic glutamate release [57,58]. MK-801(Sigma-Aldrich) was dissolved in physiological saline and administered i.p. at a concentration of 0.25 mg/kg in a volume of 15 mL/kg, 30 min prior to EtOH administration, as has been used previously in ethanol and psychostimulant sensitization studies [20,41,42,45].

View all citing articles on Scopus
View full text